Stereotaxis GenesisX EU nod marks major shift in robotic-assisted surgery market: GlobalData
Stereotaxis GenesisX EU clearance signals pivotal advancement in robotic-assisted surgery, highlighting the industry's shift towards precision and innovation
The EU clearance of Stereotaxis’ endovascular robotic system “GenesisX” marks a significant advancement in the rapidly growing field of robotic-assisted surgery. As the global market for these systems is set to surge, driven by the need for precision in minimally invasive procedures, this highlights the industry’s shift towards innovative technologies that improve surgical outcomes and redefine standards in interventional medicine, according to GlobalData.
GlobalData’s report, “Robotic Surgical Systems Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033,” reveals that the global robotic surgical systems market will grow at a compound annual growth rate of more than 12 per cent during 2023-2033.
Graysen Vigneux, Medical Analyst at GlobalData, states, “This anticipated growth underscores the expanding demand in the market, driven by several key factors: the rising need for precise and minimally invasive surgical solutions among an ageing population, a growing emphasis on value-based healthcare to improve surgical outcomes, and continuous technological advancements that are expected to yield more efficient and less invasive robotic surgical platforms.”
Stereotaxis says that GenesisX is designed to facilitate minimally invasive endovascular procedures, offering physicians enhanced control and precision. Leveraging advanced magnetic navigation technology, the system allows for precise manipulation of catheters within the vascular system, even in the most complex anatomical situations. This capability not only improves the accuracy and safety of procedures but also reduces the risk of complications, such as vessel damage or procedural errors.
As the system gains traction in Europe, it may set a precedent for the adoption of similar technologies in other regions, further driving the global market for robotic-assisted interventions.
“Stereotaxis’ achievement in securing EU clearance for GenesisX underscores the growing importance of robotics in enhancing the quality of care in interventional medicine. As hospitals and healthcare providers seek to improve outcomes and efficiency, the role of advanced robotic systems like Stereotaxis’ will become increasingly critical,” adds Vigneux.
- Advertisement -